Clinical Trials Logo

MYD88 Gene Mutation clinical trials

View clinical trials related to MYD88 Gene Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04273139 Active, not recruiting - Clinical trials for Waldenstrom Macroglobulinemia

Ibrutinib + Venetoclax in Untreated WM

Start date: July 9, 2020
Phase: Phase 2
Study type: Interventional

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this study are: - Venetoclax - ibrutinib